Be Biopharma Email Format
Biotechnology ResearchMassachusetts, United States51-200 Employees
Be Biopharma, a Cambridge, Massachusetts-based biotechnology company, is developing Engineered B Cell Medicines to treat Hemophilia B and other genetic diseases, cancer, and other serious conditions. The organization emphasizes collaboration among scientists, technologists, manufacturing experts, and business professionals to advance a new class of cell therapies. Operating in the biotechnology research industry, Be Biopharma targets a patient population with limited options for these diseases. In January 2025, Be Biopharma expanded its governance with the appointment of Melissa McCracken to its Board of Directors.